Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05708950). This is a study registration, not published results. Lead sponsor: Kineta Inc.. Recruitment status: COMPLETED. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 40 participants (ACTUAL). Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer. Interventions: DRUG: KVA12123 - Dose Escalation; DRUG: KVA12123 Plus Pembrolizumab - Dose Escalation; DRUG: KVA12123 - Dose Expansion; DRUG: KVA12123 Plus Pembrolizumab - Dose Expansion. Primary outcome measures: Adverse Events , Through study completion, an average of 1 year; AEs related to study drug , Through study completion, an average of 1 year; Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) , Through study completion, an average of 1 year. Brief summary: This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors. The study included dose escalation and planned dose expansion phases. Only the dose escalation phases were conducted. The planned dose expansion phase were not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern. The study sought to assess the safety of KVA12123 \[TBS-2025\] given alone or with pembrolizumab and to identify appropriate doses for future clinical trials. Participants in the doses for future clinical trials. Participants in the dose escalation phases visited study sites for treatment and safety assessments. These assessments included blood samples, imaging scans, physical examinations, and heart function tests.